Top Healthcare Investors
Patient Square Capital leads at $19 billion as of May 2026 — a pure-play that grew from a record $3.9 billion debut fund. Ranked by healthcare-dedicated capital, not total AUM.
Largest pure-play: Patient Square Capital ($19B) · Linden's Fund VI: $5.4B, oversubscribed (2025) · 2025 healthcare PE deal value: record ~$191B
A healthcare investor commits dedicated capital to healthcare services, products, technology, and care delivery — as distinct from biotech venture, which funds drug development and is ranked separately. Patient Square Capital leads at $19 billion as of May 2026, per the firm's own disclosures. Its trajectory is the story of the category: the Menlo Park firm closed a record $3.9 billion debut fund and has scaled into the largest pure-play healthcare investor. Linden Capital Partners ranks second at roughly $14 billion of regulatory assets — the largest dedicated middle-market healthcare private-equity firm — after closing an oversubscribed $5.4 billion Fund VI in 2025. Welsh, Carson, Anderson & Stowe, which has deployed more than $11 billion of equity across 100-plus healthcare companies, is third at an estimated $13.4 billion. Pure-plays are ranked on firm AUM; multi-sector firms on their dedicated healthcare pools.
The more consequential shift is who now counts as a healthcare investor. General Catalyst, a venture firm, bought a health system outright: its HATCo subsidiary acquired Summa Health in 2025 to run its transformation model from the inside. TPG manages a $7.1 billion dedicated healthcare pool within a roughly $300 billion platform and has put more than $21 billion into the sector over decades; KKR and New Mountain Capital run multibillion-dollar healthcare books inside larger firms; a16z has raised roughly $3.3 billion across its Bio + Health funds, including a $500 million collaboration with Eli Lilly. Behind them, a specialist venture bench — Oak HC/FT at more than $7 billion after raising nearly $2 billion for its latest fund, Town Hall Ventures, Frist Cressey, Flare Capital — funds the digital-health layer. Pure-play AUM, dedicated pools, and deployed capital are not perfectly comparable; the footnote details each basis.
The backdrop is a record market. Global healthcare private-equity deal value reached an estimated $191 billion in 2025 across 445 buyouts, the second-highest count on record, and exit value surged to roughly $156 billion from $54 billion a year earlier, per Bain's 2026 Global Healthcare Private Equity Report. Venture followed the same curve: US digital-health funding hit $14.2 billion, the highest since 2022, with AI companies taking 54% of the money, and healthcare AI drew nearly $18 billion across the US and Europe — 46% of all healthcare venture investment. Global digital-health funding reached about $28.8 billion, up 9% on the year. After three lean years, capital is moving again, and it is moving disproportionately toward AI. Every firm here links to its Altss profile — strategy, leadership, and deal activity, kept current.
Top Healthcare Investors: by the numbers
- Patient Square Capital manages $19 billion as of May 2026, making it the largest pure-play healthcare investor, per the firm.
- Linden Capital Partners reported roughly $14 billion of regulatory AUM as of December 31, 2025, and closed its oversubscribed $5.4 billion Fund VI during the year, per the firm.
- Global healthcare PE deal value reached a record estimated $191 billion in 2025 across 445 buyouts, per Bain's 2026 Global Healthcare Private Equity Report.
- US digital-health venture funding hit $14.2 billion in 2025, the highest since 2022, with AI companies taking 54% of the total, per Rock Health.
- Healthcare PE exit value surged to roughly $156 billion in 2025 from $54 billion in 2024, per Bain.
- Oak HC/FT holds more than $7 billion in AUM after raising nearly $2 billion for its latest fund, per the firm.
Top Healthcare Investors
mid-2026 (data primarily YE2025–Q1/Q2 2026 disclosures and reports)
Ordered by healthcare-dedicated capital: firm AUM for pure-play specialists, and dedicated healthcare funds, pools, or deployed healthcare equity for multi-sector firms. The two bases are not perfectly comparable, so each note states which one applies.
| # | Firm | Scale | Headquarters |
|---|---|---|---|
| 1 | Patient Square CapitalDedicated healthcare private-equity firm investing across services, products, and technology; the largest pure-play healthcare investor, built from a record $3.9B inaugural fund. | $19B AUM | Menlo Park, USA |
| 2 | Linden Capital PartnersLargest dedicated middle-market healthcare PE firm, focused exclusively on services, products, and distribution; closed an oversubscribed $5.4B Fund VI in 2025. | ~$14B regulatory AUM | Chicago, USA |
| 3 | Welsh, Carson, Anderson & Stowe (WCAS)Specialist PE investing exclusively in healthcare and technology; has deployed $11B+ of equity across 100+ healthcare companies. Its latest flagship, WCAS XIV, closed above $5B in 2023, and Fund XV is being raised. | ~$13.4B AUM (est.; >$31B cumulative raised HC+tech) | New York, USA |
| 4 | Oak HC/FTGrowth-equity and venture firm spanning healthcare and fintech, with an AI and digital-health tilt; raised nearly $2B for its latest fund in 2026 and counts 100+ portfolio companies. | $7B+ AUM | Stamford, USA |
| 5 | TPG (Healthcare Partners / Capital Healthcare)Runs the dedicated $7.1B TPG Healthcare Partners pool within a multi-decade franchise that has deployed $21B+ including co-investment across care delivery, technology, and services; total firm AUM is roughly $303-306B. | $7.1B dedicated THP + $21B+ deployed HC | Fort Worth / San Francisco, USA |
| 6 | New Mountain Capital (PE side)Growth-oriented PE firm with a major healthcare and healthtech book — Datavant, the Signify Health exit, payments and technology rollups; healthcare is a core focus rather than a dedicated fund. | ~$60B total AUM (significant HC book; multi-$B platforms) | New York, USA |
| 7 | KKR (Healthcare strategies)Global PE firm with a long healthcare record across hospitals, services, and technology; runs dedicated Health Care Strategic Growth funds, with a $1.45B prior vintage, and has been deploying into Indian healthcare. | Large multi-B HC exposure within ~$744–758B total AUM; dedicated growth funds e.g. prior $1.45B | New York, USA |
| 8 | General Catalyst (incl. HATCo / Health Assurance)Venture and growth investor whose Health Assurance strategy goes beyond backing startups: its HATCo subsidiary acquired the Summa Health system in 2025 and partners with health systems on transformation. | $43B+ total AUM; dedicated Health Assurance capital (e.g. $750M allocation + HATCo) | Cambridge / multi, USA |
| 9 | a16z Bio + Health (Andreessen Horowitz)Andreessen Horowitz's dedicated Bio + Health strategy, with roughly $3.3B raised across four funds plus a $500M collaboration with Eli Lilly; invests in healthtech and services beyond pure biotech. | ~$3.3B+ cumulative Bio+Health funds (est.) + Growth health activity | Menlo Park / SF, USA |
| 10 | Town Hall VenturesHealthcare VC investing in care for underserved communities, with a growing AI focus; closed its largest fund, the $440M Fund IV, and counts 40+ companies including multiple unicorns. | ~$1.3–1.4B AUM | New York, USA |
| 11 | Frist Cressey VenturesHealthcare services and technology VC co-founded by Senator Bill Frist and Bryan Cressey; closed an oversubscribed $425M Fund IV, backing care delivery and AI-native companies. | Nearly $1B AUM | Nashville, USA |
| 12 | Flare Capital PartnersEarly healthtech VC backing the software, data, and AI operating layer of healthcare; closed Fund III at $350M in 2022 and has backed 80+ companies. | Nearly $1B AUM | Boston, USA |
| 13 | Define VenturesOne of the largest early-stage digital-health pure-plays, investing from incubation through Series B; raised $460M across Fund III and an Opportunities fund in 2023. | $800M AUM | Silicon Valley, USA |
| 14 | Transformation CapitalGrowth-equity firm focused exclusively on digital health, healthcare IT, and services; Fund III closed at its $800M hard cap in 2022, on top of more than $800M raised across earlier funds. | ~$1.3B+ (est. across funds; $800M Fund III) | Boston, USA |
| 15 | 7wireVenturesDigital-health VC investing from early stage through growth; closed the $217M GO Fund in 2023, taking AUM above $500M. | >$500M AUM | Chicago / Illinois, USA |
| 16 | SV Health InvestorsSpecialist multi-stage healthcare platform spanning services, technology, biotech, and devices, investing across the US and Europe on a 30-year track record. | $4.0B historical commitments / ~$4B AUM | Boston, USA |
| 17 | General Atlantic (Healthcare)Global growth-equity firm with a substantial healthcare franchise in value-based care and tech-enabled services; the healthcare team has deployed $4B+ since 2014, more than $1B of it in 2024-25. | >$4B deployed HC since 2014 (team-led); firm ~$126B total AUM | New York, USA |
| 18 | Optum Ventures (corporate)The strategic venture arm of Optum and UnitedHealth Group, with 65+ portfolio companies in healthcare innovation; included as the sector's most prominent corporate investor rather than an independent fund manager. | >$2B AUM | USA (Optum/UHG) |
Pure-play specialists are measured on firm AUM; multi-sector firms on dedicated healthcare pools or deployed healthcare equity, so figures mix current AUM with cumulative raised or deployed capital, and venture scale with buyout scale. Estimates fill gaps where 2026 disclosures are sparse — WCAS, Transformation Capital, and Define Ventures rest partly on 2022-23 fund data. The scope favors healthcare services and technology over pure biotech, which is ranked separately, and Optum Ventures is included as a corporate investor. The ranking reflects scale, not performance.
How we rank — pure-plays vs. healthcare arms
Firms are ordered by healthcare-dedicated capital. For pure-play specialists such as Patient Square and Linden, that means firm AUM; for multi-sector firms such as TPG, KKR, and General Catalyst, it means the dedicated healthcare fund, pool, or deployed healthcare equity.
The bases differ — private-equity dry powder is not venture AUM, and capital deployed over a decade is not a current fund — so adjacent ranks are better read as roughly equivalent scale than as a strict order.
Top Healthcare Investors — common questions
What is the largest healthcare investor?
Why isn't a biotech firm like OrbiMed on this list?
Why does a venture firm own a hospital system?
How big was healthcare private equity in 2025?
The full picture, firm by firm
Altss keeps a live profile on every investor above — funds, leadership, and healthcare deal flow — alongside coverage of 30,000+ institutional investors, RIAs, and family offices.